Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT

Current Heart Failure Reports

Volumn 14, Issue 4, 2017, Pages 217-222

  Patel, Ravi B ^a   Shah, Sanjiv J ^a   Fonarow, Gregg C ^b   Butler, Javed ^c   Vaduganathan, Muthiah ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Heart failure with preserved ejection fraction; International variation; Mineralocorticoid receptor antagonists; Spironolactone; Study design

Indexed keywords

BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; DIURETIC AGENT;

BIOBANK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL HETEROGENEITY; CELL SPECIFICITY; CLINICAL TRIAL; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; IMAGING; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; REVIEW; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

DIURETICS; HEART FAILURE; HUMANS; MEDICATION ADHERENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85021250142     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-017-0336-x     Document Type: Review

References (35)

1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33. doi:10.1016/j.jacc.2013.11.053.
2. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J. 2012;33(2):203–12. doi:10.1093/eurheartj/ehr292.
3. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689–97. doi:10.1056/NEJMra000050.
4. •• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017; doi:10.1016/j.jacc.2017.04.025. The updated 2017 ACC/AHA/HFSA clinical practice guidelines for the management of patients with HF.
5. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781–91. doi:10.1001/jama.2013.905.
6. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634–42. doi:10.1016/j.cardfail.2011.04.007.
7. Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, et al. Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review. J Am Heart Assoc. 2015;4(10):e002137. doi:10.1161/JAHA.115.002137.
8. •• Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92. doi:10.1056/NEJMoa1313731. The TOPCAT trial, a phase 3, international, double-blind, placebo-controlled trial of spironolactone in patients with HFpEF.
9. •• Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. doi:10.1161/CIRCULATIONAHA.114.013255. The pre-specified region-specific subgroup analysis of the TOPCAT trial demonstrated marked global heterogeneity in clinical profiles, event rates, and response to spironolactone.
10. de Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT—new insights into regional variation. N Engl J Med. 2017;376(17):1690–2. doi:10.1056/NEJMc1612601.
11. •• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT). https://clinicaltrials.gov/ct2/show/NCT02901184. Accessed May 21 2017. The SPIRRIT trial, a planned phase 4 registry-based RCT that will evaluate the efficacy of spironolactone in patients with HFpEF.
12. Ferreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail. 2015;17(9):893–905. doi:10.1002/ejhf.326.
13. Bristow MR, Enciso JS, Gersh BJ, Grady C, Rice MM, Singh S, et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC Basic Transl Sci. 2016;1(3):180–9. doi:10.1016/j.jacbts.2016.03.001.
14. Greene SJ, Gheorghiade M. Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? Eur J Heart Fail. 2015;17(9):875–8. doi:10.1002/ejhf.335.
15. Vaduganathan M, Butler J, Gheorghiade M. Transforming drug development in heart failure: navigating the regulatory crossroads. Circ Heart Fail. 2016;9(10) doi:10.1161/CIRCHEARTFAILURE.116.003192.
16. Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, et al. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev. 2014;19(2):135–52. doi:10.1007/s10741-012-9361-8.
17. Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O’Connor CM, et al. Site selection for heart failure clinical trials in the USA. Heart Fail Rev. 2015;20(4):375–83. doi:10.1007/s10741-015-9473-z.
18. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol. 2015;65(16):1668–82. doi:10.1016/j.jacc.2015.03.043.
19. Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(6):870–6. doi:10.1016/j.amjcard.2012.05.014.
20. Greene SJ, Fonarow GC, Solomon SD, Subacius HP, Ambrosy AP, Vaduganathan M, et al. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017;19(4):552–62. doi:10.1002/ejhf.674.
21. Patel RB, Vaduganathan M, Shah SJ, Butler J. Atrial fibrillation in heart failure with preserved ejection fraction: insights into mechanisms and therapeutics. Pharmacol Ther. 2016; doi:10.1016/j.pharmthera.2016.10.019.
22. Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail. 2016;18(1):54–65. doi:10.1002/ejhf.442.
23. Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail. 2017;5(4):241–52. doi:10.1016/j.jchf.2016.11.015.
24. D’Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail. 2015;17(12):1231–9. doi:10.1002/ejhf.430.
25. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588–95. doi:10.1161/CIRCHEARTFAILURE.109.930701.
26. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447–56. doi:10.1016/j.jacc.2013.09.052.
27. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269–79. doi:10.1161/CIRCULATIONAHA.114.010637.
28. Vaduganathan M, Patel RB, Butler J, Metra M. Integrating electronic health records into the study of heart failure: promises and pitfalls. Eur J Heart Fail. 2017 (in press).
29. Blecker S, Katz SD, Horwitz LI, Kuperman G, Park H, Gold A, et al. Comparison of approaches for heart failure case identification from electronic health record data. JAMA Cardiol. 2016;1(9):1014–20. doi:10.1001/jamacardio.2016.3236.
30. Jonnalagadda SR Adupa AK, Garg RP, Corona-Cox J, Shah SJ. Text mining of the electronic health record: an information extraction approach for the automated identification and subphenotyping of HFpEF patients for clinical trials. J Cardiovasc Transl Res. 2017 (in press).
31. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65–74. doi:10.1056/NEJMra1510061.
32. Pfeffer MA, Braunwald E. Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiol. 2016;1(1):7–8. doi:10.1001/jamacardio.2015.0356.
33. Mitter SS, Shah SJ. Spironolactone for management of heart failure with preserved ejection fraction: whither to after TOPCAT? Curr Atheroscler Rep. 2015;17(11):64. doi:10.1007/s11883-015-0541-6.
34. ACCESS CV, Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, et al. Sharing data from cardiovascular clinical trials—a proposal. N Engl J Med. 2016;375(5):407–9. doi:10.1056/NEJMp1605260.
35. Taichman DB, Backus J, Baethge C, Bauchner H, de Leeuw PW, Drazen JM, et al. Sharing clinical trial data—a proposal from the International Committee of Medical Journal Editors. N Engl J Med. 2016;374(4):384–6. doi:10.1056/NEJMe1515172.